*February 2022*
View the video or read the transcript of expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.
We are a group of lung cancer patients with EGFR mutations who have developed resistance to at least one targeted treatment drug, or who face probable resistance in the future. Caregivers are also welcome. We are here to share treatment experiences, information about clinical trials, breaking news about research developments, and other information with each other.